Earnings Summary

Corcept Therapeutics Inc’s revenue jumped 13.86% since last year same period to $117.72Mn in the Q2 2023. On a quarterly growth basis, Corcept Therapeutics Inc has generated 11.42% jump in its revenue since last 3-months.

Corcept Therapeutics Inc’s net profit fell -0.2% since last year same period to $27.36Mn in the Q2 2023. On a quarterly growth basis, Corcept Therapeutics Inc has generated 73.06% jump in its net profits since last 3-months.

Corcept Therapeutics Inc’s net profit margin fell -12.35% since last year same period to 23.24% in the Q2 2023. On a quarterly growth basis, Corcept Therapeutics Inc has generated 55.33% jump in its net profit margins since last 3-months.

Corcept Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at 0.24 - a 4.35% jump from last quarter’s estimates.

Corcept Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at 0.24.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Corcept Therapeutics Inc’s return on assets (ROA) stands at 0.12.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Corcept Therapeutics Inc’s return on equity (ROE) stands at 0.22.